Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has shared an announcement.
Sumitomo Pharma Co., Ltd. reported a significant foreign exchange loss of 6,747 million yen for the first quarter of the fiscal year ending March 31, 2026, primarily due to the valuation of foreign currency-denominated liabilities held by its overseas subsidiaries. Despite these finance costs, the company has not revised its financial forecasts, as future fluctuations in foreign exchange rates are uncertain.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Osaka, Japan, focusing on the development and distribution of pharmaceutical products. It operates in the healthcare industry and is listed on the Prime Market of the Tokyo Stock Exchange.
Average Trading Volume: 12,362,924
Technical Sentiment Signal: Buy
Current Market Cap: Yen451.7B
For a thorough assessment of 4506 stock, go to TipRanks’ Stock Analysis page.